Clinical trials: Metastatic Kidney Carcinoma
Breast Cancer, Gestational Trophoblastic Tumor
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side…
- Conditions
- Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma
- Trial name
- NCT00004157
- Testing
- filgrastim, recombinant interleukin-11
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Healthy Subject, Metastatic Renal Cell Cancer
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
This pilot research trial studies the use of the Myeloid Derived Suppressor Cells Clinical Assay in finding and monitoring kidney cancer.
- Conditions
- Healthy Subject, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage I Renal Cell Cancer
- Trial name
- NCT02664883
- Testing
- Computed Tomography, Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Renal Cell Carcinoma
Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
The purpose of this research study is to further define an effective strategy for people with renal cell carcinoma and to learn the safety and effectiveness of two different types of sunitinib-refractory treatments: Bevacizumab…
- Trial name
- NCT00556205
- Testing
- Sunitinib, Bevacizumab
- Sponsor
- Massachusetts General Hospital
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected…
- Conditions
- Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT02599324
- Testing
- ibrutinib, everolimus, paclitaxel
- Where
- 65 sites in United States, South Korea and 2 more
- Volunteers
- 263 people
- Sponsor
- Pharmacyclics LLC.
Clear Cell Renal Cell Carcinoma
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients…
- Trial name
- LAG-BOOST (NCT07223541)
- Testing
- Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Oklahoma
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer
The reason for doing this study is to see if cancer will respond to immune therapy after transplantation of blood stem cells (from the bone marrow) using a new kind of treatment regimen that is less toxic than that previously…
- Trial name
- NCT00005851
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas
MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas
This Phase II study will evaluate toripalimab plus axitinib in adults with previously untreated, synchronous metastatic non-clear cell renal cell carcinoma and renal medullary carcinomas whose primary kidney tumor remains in…
- Trial name
- MANTIS-RCC (NCT07816770)
- Testing
- Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy
- Volunteers
- 30 people
- Sponsor
- Fudan University
Carcinoma, Renal Cell
ATN-161 in Advanced Renal Cell Cancer
The purpose of this study is to determine an active dose of ATN-161 for future studies while establishing preliminary evidence of effectiveness in patients with renal cell cancer.
- Trial name
- NCT00131651
- Testing
- ATN-161
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Attenuon
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Renal Cell Carcinoma
RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma
The purpose of this study is to look at the effects of a procedure called radiofrequency ablation on kidney tumors from patients who are undergoing antiangiogenic treatment.
- Trial name
- NCT00601120
- Testing
- Radiofrequency Ablation
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 582 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma
This clinical trial studies the effects of occupational therapy fatigue management in patients with renal cell cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04961320
- Testing
- Occupational Therapy, Questionnaire Administration
- Sponsor
- City of Hope Medical Center
Kidney Cancer
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
RATIONALE: Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00541008
- Testing
- sunitinib malate
- Where
- 22 sites in France
- Volunteers
- 92 people
- Sponsor
- UNICANCER
Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation…
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
- Trial name
- SPARCC (NCT07123090)
- Testing
- Sasanlimab, Palbociclib, Axitinib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Stephanie Berg
Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
PSMA Therapy and Immunotherapy in Kidney Cancer
This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I\&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell…
- Trial name
- NCT06361810
- Testing
- Pembrolizumab, 177Lu-PNT2002, (F-18)-DCFPyL
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Renal Carcinoma Metastatic
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order to delay the resistance to the anti VEGFR-TKI and decrease the related toxicity…
- Trial name
- TIDE-A (NCT04698213)
- Testing
- Axitinib Oral Tablet, Avelumab
- Where
- 20 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Consorzio Oncotech
Metastatic Cancer, Metastatic Melanoma
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Background: A new cancer treatment involves collecting white blood cells from an individual, modifying them to secrete IL-2 and target the ESO-1 protein expressed on some cancers, and returning them to the body.
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer
- Trial name
- NCT01457131
- Testing
- Fludarabine, Cyclophosphamide, IL-12 & Anti-NY ESO1 TCR PBL
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00087022
- Testing
- girentuximab
- Where
- 56 sites in United States, Argentina and 2 more
- Volunteers
- 864 people
- Sponsor
- Heidelberg Pharma AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.